Loading stock data…
NEO
$9.44+0.18 (+1.94%)
After Hours$9.80+0.36 (+3.86%)· Last close May 1
NeoGenomics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
NeoGenomics, Inc. in the Healthcare sector is trading at $9.44. The stock is currently 31% below its 52-week high of $13.74, remaining 0.2% above its 200-day moving average. Technical signals show neutral RSI of 68 and bullish MACD crossover, explaining why NEO maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 68) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$9.44
Potential Upside
5%
Whystock Fair Value$9.91
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus8 analysts
Buy
Mean target$13.81+46.3%
Range$11.00 – $17.00
Fundamentals
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical compani...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.03B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.71
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-12.44%
Volume
Today's trading volume
2.16M
Recent News
NeoGenomics Shares Jump on Earnings and Analyst Upgrades
NeoGenomics Inc. (NASDAQ:NEO) shares climbed 7.
NeoGenomics Inc (NEO) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
NeoGenomics Inc (NEO) reports an impressive 11% revenue growth, driven by clinical advancements and strategic market expansions, despite challenges in non-clinical sectors.
NeoGenomics Q1 Earnings Call Highlights
NeoGenomics (NASDAQ:NEO) reported first-quarter 2026 results that management said reflected continued momentum in its clinical business and growing contributions from newer, higher-value oncology tests. Total revenue rose 11% year-over-year to $186.7 million, exceeding the company’s guidance, while
NeoGenomics (NEO) Q1 2026 Earnings Transcript
With me today to discuss the results are Tony Zook, Chief Executive Officer, Abhishek Jain, Chief Financial Officer, and Warren Stone, President and Chief Operating Officer. During this call, we will make forward-looking statements regarding our future financial and business performance, planned future operations and related expectations with respect to timing and performance, future financial position, future revenue, growth potential and expected growth drivers, projected costs and capital expenditure, prospects and plans, estimated market size and position, and objectives of management and financial guidance.
NeoGenomics (NEO) Q1 2025 Earnings Transcript
With me today to discuss the results are Tony Zook, Chief Executive Officer; Jeff Sherman, Chief Financial Officer; Warren Stone, President and Chief Operating Officer; and Andrew Lukowiak, Chief Innovation Officer. Additional members of the management team are available for Q&A, including Kareem Saad, Head of Strategy and Transformation; Ali Olivo, General Counsel and Head of Business Development; and Dr. Nate Montgomery, VP of Clinical Services.